Known as the place where healthcare innovators go to be bold, HLTH 2024 returned to the Venetian Convention Center in Las Vegas for four days of sessions, exhibits and networking. Leaders across healthcare shared ambitious ideas on how we can work together to run healthier lives, utilizing technology and expertise to catch disease sooner, treat it more effectively and work toward better health.
One highlight of the event was speaking with MedCity News’ Marissa Plescia for a Heard @ HLTH interview. We discussed the keys to lasting innovation - not just building great products or getting patients to use them, but importantly, keeping them happy and supported so they can persist with their treatment. Traditionally, pharmaceutical companies have struggled to keep patients adherent to their therapies, which prevents them from achieving the best clinical outcomes.
To tackle this challenge, BrightInsight works with top 30 biopharmaceutical companies to deeply understand a particular disease, how a therapy works, identify key pain points to patient adherence, and define a digital experience to address those pain points. Digital delivers a better patient experience –making patients more engaged and more adherent, while driving a better clinical outcome. Using our BrightInsight Digital Platform to build innovative digital tools, we have use cases that represent rare diseases as well as common and chronic conditions.
As a FierceHealthcare’s show recap notes, the conversations around AI are becoming less fantastical and more centered around what regulations and standards should be implemented to ensure accuracy and build trust among patients and providers while keeping momentum strong. Clinical AI company, Aidoc, and Nvidia announced their partnership to develop a set of guidelines for AI implementation called BRIDGE: the Blueprint for Resilient Integration and Deployment of Guided Excellence for AI adoption. In parallel, most health systems are running generative AI pilots to identify use cases that will most benefit from this technology.
This summer, BrightInsight announced a partnership with Lirio leveraging AI to enhance our biopharma customers’ patient companion apps by identifying engagement and personalization opportunities and creating a hyper-personalized experience for app users. Nudges can be delivered to drive sustained engagement, adherence and behavior change.
For the first time, the industry is using the power of digital to more broadly engage people outside the walls of a clinic or hospital. This allows biopharma companies to gain data we’ve never had before, leading to insights that not only better support the patient in that therapy, but also inform R&D, understanding of real-world evidence and the performance of drugs.
We can then identify who the right populations should be, the right price points, and how to improve market access. This will unlock a whole set of improvements in these core areas of pharma with the power of data and combined with the capabilities we are building with generative AI to optimize patient experience and outcomes.
One of the key attractions of HLTH is that it draws innovators across the healthcare ecosystem, including entrepreneurs, investors, life sciences, health systems and patients – all with an infectious energy and willingness to collaborate to meet our common mission of better health. This year benefited from more clinical representation, including the Nurses@HLTH program, deepening clinical involvement in bringing more fitting solutions to market.
Women’s health, oral health and rural health were given a needed spotlight as areas for continued innovation, demonstrating how strength in these areas impacts all of healthcare. Evidence of this support came when First Lady of the United States Jill Biden, Ph.D., announced $110 million in federal funding for women’s health research and product development.
The patient journey is shifting and we fundamentally believe that digital companion apps can enhance it by providing more relevant, timely and engaging interventions that support patients where they are and where they most need support. These apps require the ability to be configured, localized and scaled across disease states, locations and therapeutics, which is where BrightInsight can help.
Key Takeaway: While healthcare takes time to change, we are hitting an inflection point with digital health. As we increasingly turn to companion apps and data analytics to improve medication adherence and the patient experience, BrightInsight is well-positioned to deliver the critical underlying infrastructure – ensuring these digital tools are built with industry-leading scalability, functionality, configurability, speed, compliance and global availability now and well into the future.